

~~03C0~~

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

JAVITT, Dr. daniel c., et al.

Appln. No.: 10/059,362

Confirmation No.: 8660

Group Art Unit: Not Yet Assigned

Filed: January 31, 2002

Examiner: Not Yet Assigned

For: GLYCINE SITE FULL AGONIST FOR TREATING A PSYCHOSIS

SECOND PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claim 9 without prejudice or disclaimer.

Please add the following new claims:

10. A pharmaceutical composition comprising (i) at least one agonist of the glycine site of a NMDA receptor and (ii) a second therapeutic agent selected from the group consisting of antipsychotics, wherein

the agonist is selected from the group consisting of D-serine and a precursor of D-serine.

11. The pharmaceutical composition of claim 10 wherein the antipsychotic is selected from the group consisting of thioridazine, clozapine and chlorpromazine.

12. A method for treating a psychosis characterized by dysfunction or dysregulation of NMDA neurotransmission in a patient, the method comprising administering to the patient

Year	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099
1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	

SECOND PRELIMINARY AMENDMENT
APPLN. SERIAL NO. 10/059,362

diagnosed as suffering from the psychosis a therapeutically effective amount of an agonist of the glycine site of a NMDA receptor wherein the agonist is selected from the group consisting of D-serine and a precursor of D-serine.

13. The method of claim 12 wherein the psychosis is schizophrenia.
14. The method of claim 13 wherein the agonist is D-serine.

SECOND PRELIMINARY AMENDMENT
APPLN. SERIAL NO. 10/059,362

REMARKS

Entry is respectfully requested.

Applicant is filing concurrently herewith a Request for Interference with U.S. 6,228,875.

As explained in the Request under 37 C.F.R. § 1.607, each of the above claims 10-14 corresponds to the proposed count.


In accordance with subparagraph (a) (5) of 37 C.F.R. § 1,607, the terms of claims 10-14, since said claims were not previously in the current application, are applied to the disclosure of the instant application in the Request for Interference. Accordingly, that information is not duplicated herein.

Also, as explained in the 37 C.F.R. § 1.607 request, Applicant is entitled to the benefit of grand-parent application 09/212,273 filed December 16, 1998 (now U.S. Patent 6,162,827), in turn a divisional application of U.S. serial No. 08/759,714 filed December 6, 1996 (now U.S. patent 5,854,286) for at least one embodiment within the proposed count and within Applicant's claims, thereby setting forth a prima facie case of prior invention in relationship to the filing date of April 14, 1999 of U.S. patent 6,228,875. Indeed, Applicant's effective filing date of December 6, 1996 for at least one embodiment of the common invention is also prior to the provisional application filing date of April 14, 1998, the benefit of which has been claimed by the '875 patentee.

SECOND PRELIMINARY AMENDMENT
APPLN. SERIAL NO. 10/059,362

Applicant requests that an interference be declared in accordance with the Request under
37 C.F.R. § 1.607 filed concurrently herewith.

Respectfully submitted,


Louis Gubinsky
Registration No. 24,835

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: May 6, 2002

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claim 9 is canceled without prejudice or disclaimer.

Claims 10-14 are added as new claims.

10. A pharmaceutical composition comprising (i) at least one agonist of the glycine site of an NMDA receptor and (ii) a second therapeutic agent selected from the group consisting of antipsychotics, wherein

the agonist is selected from the group consisting of D-serine and a precursor of D-serine.

11. The pharmaceutical composition of claim 10 wherein the antipsychotic is selected from the group consisting of thioridazine, clozapine and chlorpromazine.

12. A method for treating a psychosis characterized by dysfunction or dysregulation of NMDA neurotransmission in a patient, the method comprising administering to the patient diagnosed as suffering from the psychosis a therapeutically effective amount of an agonist of the glycine site of a NMDA receptor wherein the agonist is selected from the group consisting of D-serine and a precursor of D-serine.

13. The method of claim 12 wherein the psychosis is schizophrenia.

14. The method of claim 13 wherein the agonist is D-serine.